W. Timothy Garvey, MD
Nutrition Sciences at the University
Biography & Research Background
W. Timothy Garvey, MD is a professor in the Department of Nutrition Sciences at the University of Alabama at Birmingham. He served as principal investigator for the pivotal Phase 3 REDEFINE program evaluating cagriniltide combined with semaglutide (CagriSema) for weight loss. His landmark trial demonstrated 22.7% weight loss with CagriSema in 3,417 adults with overweight or obesity, along with significant cardiovascular benefits including 10.9 mmHg systolic blood pressure reduction. His key publications include "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity" (2025, New England Journal of Medicine) and "CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1" (2026, Hypertension). W. Timothy Garvey is being referenced as one of the leading scientists involved in cagriniltide research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
W. Timothy Garvey, MD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
W. Timothy Garvey, MD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.